Serological response to vaccines against SARS-CoV-2 in patients with inflammatory bowel disease

To study the serological response (SR) and tolerability of COVID-19 vaccine in patients with inflammatory bowel disease (IBD) and its relation with IBD treatment and type of vaccine. Observational, cross-sectional study in patients with IBD vaccinated against COVID-19 without known previous infectio...

Full description

Saved in:
Bibliographic Details
Published in:Gastroenterología y Hepatología (English Edition) 2023-01, Vol.46 (1), p.48-53
Main Authors: Algaba, Alicia, Romero, Sara, Granja, Alicia, Garza, Daniel, Aller, Mar, Barrero, Sara, Guerra, Iván, Gil, Marina, Pizarro, Nazaret, Ruiz, Paloma, Prieto, Santiago, Hernández, Belén, Pou, Aranzazu, Bermejo, Fernando
Format: Article
Language:English
Subjects:
Biologicals
Biológicos
COVID-19
Enfermedad inflamatoria intestinal
Inflammatory bowel disease
Original
SARS-CoV-2 vaccine
Vacuna infección SARS-CoV-2
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To study the serological response (SR) and tolerability of COVID-19 vaccine in patients with inflammatory bowel disease (IBD) and its relation with IBD treatment and type of vaccine. Observational, cross-sectional study in patients with IBD vaccinated against COVID-19 without known previous infection. SR was analyzed by the determination of IgG antibodies against the S1 subunit. Safety was studied using a questionnaire to identify adverse effects (AE). 280 patients with IBD were included. Type of vaccines: Comirnaty® 68.8%; Spikevax® 10.8%, Vaxzevria® 18.3%, Ad26.COV2-S® 2.2%. 51.3% had AE, being 100% mild. 65% developed IgG antibodies after vaccination. The SR was higher for vaccines with mRNA technology (100% Spikevax®, 68.5% Comirnaty®) compared to those based on adenovirus vector (38.0% Vaxzevria®, 33.3% Ad26.COV2-S®) (P 
ISSN:2444-3824
2444-3824
DOI:10.1016/j.gastre.2022.05.001